CORTISOL AND HYPERTENSION

SUMMARY 1. In humans, the hypertensive effects of adrenocorticotropic hormone (ACTH) infusion are reproduced by intravenous or oral Cortisol. Oral Cortisol increases blood pressure in a dose‐dependent fashion. At a dose of 80–200 mg/day, the peak increases in systolic pressure are of the order of 15...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental pharmacology & physiology Vol. 25; no. S1; pp. S51 - S56
Main Authors Kelly, JJ, Mangos, G., Williamson, PM, Whitworth, JA
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.11.1998
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:SUMMARY 1. In humans, the hypertensive effects of adrenocorticotropic hormone (ACTH) infusion are reproduced by intravenous or oral Cortisol. Oral Cortisol increases blood pressure in a dose‐dependent fashion. At a dose of 80–200 mg/day, the peak increases in systolic pressure are of the order of 15mmHg. Increases in blood pressure are apparent within 24 h. 2. Cortisol‐induced hypertension is accompanied by a significant sodium retention and volume expansion. Co‐administration of the type I (mineralocorticoid) receptor antagonist spironolactone does not prevent the onset of cortisol‐induced hypertension. Thus, sodium retention is not the primary mechanism of cortisol‐induced hypertension. 3. Direct and indirect measures of sympathetic activity are unchanged or suppressed during Cortisol administration, suggesting that cortisol‐induced hypertension is not mediated by increased sympathetic tone. 4. Preliminary evidence in humans suggests that suppression of the nitric oxide system may play a role in cortisol‐induced hypertension. 5. These potential mechanisms of Cortisol action may be relevant in a number of clinical contexts, including Cushing's syndrome, apparent mineralocorticoid excess, the hypertension of liquorice abuse and chronic renal failure. There is also preliminary evidence suggesting a role for Cortisol in essential hypertension.
Bibliography:ark:/67375/WNG-CCHXG03V-M
ArticleID:CEPS51
istex:69CAAF0FE790292984FE1F6AB3E39AC10B7C7C30
ISSN:0305-1870
0143-9294
1440-1681
DOI:10.1111/j.1440-1681.1998.tb02301.x